萊茵生物(002166.SZ):約350萬美元認購Ispire定向增發的股份
格隆匯6月28日丨萊茵生物(002166.SZ)公佈,為進一步提升公司工業大麻業務的穩健發展,加強與Ispire的戰略合作關係,公司子公司Layn Holding Group,Inc.(“Holding”)於2023年6月26日(美國時間)使用自有資金3,499,995.0362美元,參與認購了Ispire定向增發的無限售條件普通股490,759股股份,認購價格為7.1318美元/股。截至公吿披露日,Ispire本次定向增發已完成,公司目前累計持有Ispire股份705,044股股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.